Table 3.

Characteristics of the patients who developed a malignancy during follow-up

SexCyclophosphamide TreatmentAge at Biopsy (yr)Type of MalignancyDied during Follow-UpCause of DeathTime between Biopsy and Malignancy (yr)Time between Treatment and Malignancy (yr)Time between Biopsy and Death or Final Follow-Up (yr)Serum Anti-PLA2R Antibodies at Review
MenNo70LungNo1.91.9n/a
MenNo37LungYesMalignancy6.97.2
MenNo64Chronic lymphocytic leukemiaNo3.46.9+
MenNo74Lymphoma n.o.s.YesMalignancy1.81.8+
MenYes45ProstateNo18.910.318.9+
MenYes33Leukemia n.o.s.YesMalignancy20.616.220.6
MenYes44ColonNo12.510.915.2+
MenYes70ProstateNo12.711.814.8n/a
WomenYes43Chronic myelofibrosisNo4.53.510.9+
MenYes57ColonNo10.79.611.5
MenYes66ProstateYesUnknown10.14.514.9+
MenYes54BladderYesMalignancy8.11.69.1+
MenYes48Chronic lymphocytic leukemiaYesCardiovascular33.98.533.9+
MenYes70Non-Hodgkin’s lymphomaYesUnknown7.67.511.1
WomenYes62LungYesMalignancy3.63.64.6+
MenYes72LarynxNo4.22.67.8+
MenYes65ColonNo5.85.67.2+
MenYes59Renal cell carcinomaNo8.04.48.0+
WomenYes66Acute myeloid leukemiaNo2.52.23.0+
MenYes79BladderNo1.71.74.1
  • In two patients, serum samples were no longer available; therefore, anti-PLA2R serostatus could not be ascertained. PLA2R, phospholipase A2 receptor; n.o.s., not otherwise specified.